EUVIMEDOpdag EUVIMED
BeobachtungsstudieOpen access · CC BY-NC 4.0

Long‐Term Proton Pump Inhibitors in Lung Transplant Recipients: Near‐Universal Use Without Clear Impact on Clinical Outcomes Over a 20‐Year Observational Study

Chen Yang Kevin Zhang, Rayoun Ramendra, Meghan Aversa, Rasheed Ghany, Jussi Tikkanen, Ella Huszti, Jonathan Yeung, Shaf Keshavjee, Lianne G Singer, Tereza Martinu

Clinical Transplantation · 2026

DOI: 10.1111/ctr.70706 ↗

At a glance

Beobachtungsstudie in Clinical Transplantation, 2026. Written by Chen Yang Kevin Zhang and 9 co-authors. Institution: Toronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada. Major MEDLINE topics: Proton Pump Inhibitors, Lung Transplantation, Gastroesophageal Reflux, Graft Rejection. 17 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: University Health Network Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Gastroesophageal reflux disease (GERD) is a known risk factor for chronic lung allograft dysfunction (CLAD), the main barrier to long‐term survival in lung transplant recipients (LTR). While proton pump inhibitors (PPI) are effective for symptomatic treatment of GERD, data are sparse on the prevalence of long‐term PPI use and association with clinical outcomes.

Methods

Single‐center retrospective cohort of adult first‐time LTR between 1999 to 2018 who were alive and CLAD‐free at 1‐year post‐transplant. PPI exposure was defined as ≥8 continuous weeks in the first year, started within 6 months post‐transplant.

Results

1308 LTR were included, with 1170 (89.4%) exposed to PPI. PPI use increased over time and remained above 90% from 2007 onwards. In multivariable analyses, LTR on PPI had similar time to CLAD and time to death/retransplant compared to those not on PPI. Similarly, no differences in outcomes were observed between LTR on once‐daily and twice‐daily dosing, or after accounting for the number of reflux episodes on 24 h pH‐impedance monitoring. Positive bronchoalveolar lavage cultures and acute rejection over the first‐year post‐transplant was also comparable.

Conclusions

Long‐term use of PPI became near‐universal without observable effect on clinical outcomes. While further research is needed, these findings question the routine use of PPI in LTR.

Subjects

MeSH terms (MEDLINE)

Proton Pump InhibitorsLung TransplantationGastroesophageal RefluxGraft RejectionGraft SurvivalPostoperative ComplicationsPrimary Graft DysfunctionHumansFemaleRetrospective StudiesMaleFollow-Up StudiesPrognosisMiddle AgedRisk FactorsSurvival RateAdult

Author keywords

chronic lung allograft dysfunctiongastroesophageal refluxlung transplantationobservational studyproton pump inhibitors

Substances

Proton Pump Inhibitors

Authors and institutions

  • Toronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada.
  • Biostatistics Research Unit, University Health Network, Toronto, Canada.

Funding

  • University Health Network Foundation

Cite

APA

Zhang, C. Y. K., Ramendra, R., Aversa, M., Ghany, R., Tikkanen, J., Huszti, E., Yeung, J., Keshavjee, S., Singer, L. G., & Martinu, T. (2026). Long‐Term Proton Pump Inhibitors in Lung Transplant Recipients: Near‐Universal Use Without Clear Impact on Clinical Outcomes Over a 20‐Year Observational Study. Clinical Transplantation. https://doi.org/10.1111/ctr.70706

Vancouver

Zhang CYK, Ramendra R, Aversa M, Ghany R, Tikkanen J, Huszti E, et al. Long‐Term Proton Pump Inhibitors in Lung Transplant Recipients: Near‐Universal Use Without Clear Impact on Clinical Outcomes Over a 20‐Year Observational Study. Clinical Transplantation. 2026. doi:10.1111/ctr.70706

BibTeX
@article{Zhang2026,
  author = {Zhang, Chen Yang Kevin and Ramendra, Rayoun and Aversa, Meghan and Ghany, Rasheed and Tikkanen, Jussi and Huszti, Ella and Yeung, Jonathan and Keshavjee, Shaf and Singer, Lianne G and Martinu, Tereza},
  title = {Long‐Term Proton Pump Inhibitors in Lung Transplant Recipients: Near‐Universal Use Without Clear Impact on Clinical Outcomes Over a 20‐Year Observational Study},
  journal = {Clinical Transplantation},
  year = {2026},
  doi = {10.1111/ctr.70706}
}
Start for free →